Assembly Biosciences Slides 27% in a Month, Oversold Yet Still Searching for a Floor

Assembly Biosciences stock fell 27% to $22.82, below moving averages and oversold, despite unanimous analyst buys. Gilead partnership uncertain; ABI-6250 Phase 2 data in Q4 2026 is key catalyst.

The disconnect between analyst conviction and market reality has rarely been starker for Assembly Biosciences. The antiviral biotech closed Friday at $22.82, capping a one-month rout of more than 27% and pushing the shares 42% below the November high of $39.71. All four analysts covering the stock maintain buy recommendations, but the price action tells a different story.

The technical picture offers little comfort. At $22.82, the stock trades well beneath both its 50-day moving average of $28.15 and the 200-day average of $29.54. The relative strength index sits at 30.4 — technically oversold territory, though in biotech that rarely guarantees a rebound. Since the start of 2025, the shares have lost roughly 32%, leaving the 12-month gain at about 44%, a remnant of the rally that carried Assembly through early autumn.

Q1 results offered no drama, but the Gilead relationship is shifting

Assembly’s first-quarter numbers, reported in May, came in ahead of expectations. Revenue of $8.2 million, generated largely from the Gilead collaboration, beat the consensus estimate of roughly $7 million. The net loss narrowed to $9.1 million. With $226.6 million in cash, management sees the balance sheet funding operations into 2028 — a buffer that should ease near-term liquidity fears.

But the partnership with Gilead is entering a more uncertain phase. In March the pharma giant opted not to exercise its option on ABI-4334, Assembly’s hepatitis B candidate, forcing the company to find a new partner for that program. Gilead locked in rights to the herpesvirus candidates ABI-5366 and ABI-1179 in late 2025, but the market is still waiting for Gilead’s formal development plan and budget. A decision on whether Assembly will join a cost-and-profit-sharing arrangement in the U.S. must be made by mid-2026 — a choice that could boost long-term returns but would demand significantly more capital now. Notably, the stock has already fallen below the $26.50 issue price of the company's most recent capital raise, a level that typically provides some psychological support.

Pipeline milestones hinge on fourth-quarter catalyst

Assembly has wrapped up Phase 1b studies for two herpes candidates and is now preparing to launch a Phase 2 trial of ABI-6250, an oral drug candidate for chronic hepatitis delta, in the fourth quarter of 2026. A separate Phase 2 study for cholestatic liver diseases is slated to begin in the first quarter of 2027.

Guggenheim reaffirmed its buy rating in May, joining the other three analysts in the bull camp. For clinical-stage biotechs, the gap between analyst optimism and stock price is nothing new — the ultimate verdict will come from the fourth-quarter milestone, when ABI-6250 data are expected.

What investors will watch next

Management is scheduled to present at the Goldman Sachs Global Healthcare Conference on June 8, an event that could provide clarity on pipeline prioritization and the evolving Gilead relationship. A clear vote of confidence from the partner on the HSV program might halt the decline, while further delays would keep the selling pressure alive. For now, Assembly remains a classic binary-story stock: technically oversold, analyst-backed, but entirely at the mercy of its next set of clinical and partnership outcomes.